SHENZHEN, China, March 28, 2013 /PRNewswire-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"), the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2012.
Fourth Quarter Financial HighlightsFor the quarter ended December 31, 2012:
Full Year 2012 Financial HighlightsFor the year ended December 31, 2012:
Mr. Fuxiang Zhang, Chief Executive Officer, commented, "As anticipated, we closed out 2012 with a solid performance in the fourth quarter, highlighted by double digit same store sales growth. Seasonal demand, our continued efforts to further diversify and optimize our product mix and our strengthening marketing efforts all contributed to our top line growth in the fourth quarter, while our focus on store performance helped increase the number of transactions per store. We continue to see opportunities in the over-the-counter ("OTC") drugs and convenience product categories. Cost control measures are starting to reduce our operating expenses and with continued improvements in same store performance and the efforts of our management team, we are expecting a better performance in 2013."
Fourth Quarter ResultsDuring the fourth quarter of 2012, the Company opened 22 new stores and closed 81 stores.
Revenue for the fourth quarter of 2012 increased by 2.1% to RMB671.9 million (US$107.8 million), compared to RMB658.0 million for the same period in 2011. Same store sales (for 2,009 stores opened before December 31, 2010) for the fourth quarter of 2012 increased by 11.6% compared to the same period in 2011. The increase in same store sales was mainly due to the closure of underperforming stores and management's efforts in promotion also contributed to the increase.
Fourth quarter revenue contribution from prescription drugs was 21.6%, OTC drugs was 40.1%, nutritional supplements was 13.3%, herbal products was 4.3% and convenience and other products was 20.7%.
Fourth quarter gross profit was RMB308.6 million (US$49.5 million), compared to RMB314.6 million in the same period of 2011. Gross margin in the fourth quarter of 2012 was 45.9%, compared to 47.8% in the same period of 2011. The decrease in gross margin was mainly due to mandatory price cuts on certain pharmaceuticals by Chinese government and changes in product mix as the Company introduced more convenience products with lower gross margin.
The Company's portfolio of private label products included 2,019 products as of December 31, 2012. Sales of private label products represented approximately 24.7% of the revenue and 34.1% of the gross profit for the fourth quarter of 2012.
Sales, marketing and other operating expenses as a percentage of revenue in the fourth quarter of 2012 decreased to 37.6%, compared to 38.0% in the same period of 2011. This decrease from the same period of last year was primarily due to the increase in same store sales.
General and administrative expenses as a percentage of revenue in the fourth quarter of 2012 was 3.4%, compared to 5.4% for the same period of 2011. The decrease was mainly due to the facts that the Company continued to implement cost management across the entire organization and the Company has written off certain long-aged payables due to those discontinued suppliers.
Impairment loss of RMB4.7 million (US$0.8 million) was recognized in the fourth quarter of 2012, which represents the reduction of the carrying amount of the property and equipment of certain underperforming stores. Impairment loss recognized in the fourth quarter of 2011 was RMB13.2 million.
Income from operations in the fourth quarter of 2012 was RMB30.2 million (US$4.9 million), compared to RMB15.6 million in the same period of 2011.
Interest income for the fourth quarter of 2012 was RMB3.5 million (US$0.6 million), compared to RMB6.6 million in the same period of 2011. Interest income decreased as a result of reduced cash balance after distribution of a special dividend in the second quarter of 2012.
Equity in income of an equity method investee was RMB1.3 million (US$0.2 million), compared to RMB1.6 million in the same quarter of 2011. The decrease was mainly due to weak performance of JZJ in the fourth quarter of 2012. The Company had 40% of equity interests in JZJ. On December 28th, the Company completed the sales of its 40% equity interests in JZJ to Yunnan Jianzhijia Holding Co., Ltd. ("JZJ Holding") for a total cash consideration of RMB 81.48 million. A gain of RMB68.4 million (US$11.0 million) was recognized in income upon completion of the sales.
The Company's effective tax rate was 23.9% for the fourth quarter, compared to 25.6% for the same period in 2011.
Net income in the fourth quarter of 2012 was RMB78.8 million (US$12.6 million), which represented RMB0.80 (US$0.13) basic and diluted earnings per American depositary share ("ADS"). This compares to net income of RMB17.7 million, which represented RMB0.17 basic and diluted earnings per ADS in the same period of 2011.
In the fourth quarter of 2012, net cash-flows from operating activities was RMB21.4 million (US$3.5 million) compared to net cash outflow of RMB30.4 million in the fourth quarter of 2011.
Fiscal Year 2012 Financial ResultsIn fiscal year 2012, the Company opened 56 new stores and closed 319 stores. As of December 31, 2012, Nepstar had a total of 2,132 stores in operation.
Total revenue for 2012 increased to RMB2,549.9 million (US$409.3 million) from RMB2,491.3 million for 2011. Same store sales (for 2,009 stores opened before December 31, 2010) for 2012 increased by 9.1% compared to 2011. The increase in revenue and same store sales was driven by constant optimization of the merchandise portfolio through diversification into non-pharmaceutical categories and the closure of underperforming stores and also the management efforts in promotion.
In 2012, revenue contribution from prescription drugs was 20.4%, OTC drugs was 39.1%, nutritional supplements was 15.7%, traditional Chinese herbal products was 3.9% and convenience and other products was 20.9%. Private label products accounted for 26.8% of total revenue and 38.0% of gross profit, respectively, compared to 30.0% of revenue contribution and 41.3% of gross profit contribution in 2011.
Gross profit was RMB1,180.5 million (US$189.5 million) for 2012, compared to RMB1,188.6 million for 2011. Gross margin was 46.3% in 2012, compared to 47.7% in 2011. The decrease in gross margin was mainly due to changes in product mix and negative impact from the mandatory price cuts on pharmaceuticals by the Chinese government.
Total operating expenses accounted for 44.2 % of total revenue in 2012, as compared to 45.6% in 2011. Income from operations was RMB46.9 million (US$7.5 million) for 2012, compared to RMB38.6 million for 2011.
Interest income for 2012 was RMB16.4 million (US$2.6 million), compared to RMB23.2 million in 2011. Dividend income from cost method investments was RMB4.5 million (US$0.7 million) for 2012, compared to RMB3.6 million in 2011. Equity in income of an equity method investee was RMB1.3 million (US$0.2 million), compared to that of RMB1.6 million in 2011. The decrease in equity in income of an equity method investee was mainly due to the weak performance of the JZJ in 2012.
The Company's effective tax rate was 34.6% in 2012, compared to 46.3% in 2011. The decrease in effective tax rate was mainly attributable to the reversal of deferred tax liabilities arising from equity method investment of RMB6.3 million as a result of dividends distributed from JZJ and the utilization of tax losses carryforwards of which valuation allowance of RMB7.0 million was previously provided for as a result of the disposal of the Company's 40% equity interest in JZJ.
Net income was RMB90.1 million (US$14.5 million) for 2012, compared to RMB35.9 million for 2011. The Company reported RMB0.90 (US$0.14) basic and diluted earnings per ADS for 2012, compared to RMB0.35 basic and diluted earnings per ADS for 2011.
Net cash-flows from operating activities was RMB52.6 million (US$8.4million) for 2012, compared to RMB108.2 million for 2011.
The total number of outstanding ordinary shares of the Company as of December 31, 2012 was 197.4 million. The weighted average number of ordinary shares in 2012 was 199.2 million. Each ADS represents two ordinary shares of the Company.
As of December 31, 2012, the Company's total cash, cash equivalents, bank deposits and restricted cash were RMB664.4 million (US$106.6 million) and its shareholders' equity was RMB1.03 billion (US$164.7 million).
On April 27, 2012, the Company announced a special cash dividend of US$0.60 per ADS. Approximately US$60.0 million was subsequently paid to shareholders.
Business Outlook"We remain cautiously optimistic about the rest of 2013," concluded Mr. Zhang. "We believe the strategic changes we have implemented to drive sales, control costs and improve store efficiencies will help us remain competitive."
Conference Call InformationThe Company will host a conference call, to be simultaneously webcasted, on Thursday, March 28, 2013 at 8:00 a.m. Eastern Time / 8:00 p.m. Beijing Time. Interested parties may participate in the conference call by dialing +1-877-407-9210 (North America) or +1-201-689-8049 (International) approximately five minutes before the call start time. A live web cast of the conference call will be available on the China Nepstar website at www.nepstar.cn.
A replay of the call will be available shortly after the conclusion of the conference call through April 4, 2013 at 11:59 p.m. Eastern Time or April 5, 2013 at 11:59 a.m. Beijing Time. An archived Web cast of the conference call will be available on the China Nepstar website at http://www.nepstar.cn. Interested parties may access the replay by dialing +1-877-660-6853 (North America) or +1-201-612-7415 (International) and entering conference ID number 409876.
About China Nepstar Chain Drugstore Ltd.China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is China's largest retail drugstore chain based on the number of directly operated stores. As of December 31, 2012, the Company had 2,132 stores across 73 cities, one headquarter distribution center and 16 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmacy services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products including consumables. Nepstar's strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the continuing economic growth in China and to take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to http://www.nepstar.cn.
Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's strategic operational plans and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Exchange Rate InformationThe United States dollar (US$) amounts disclosed in this press release are presented solely for the convenience of the reader. Translations of amounts from RMB into United States dollars were calculated at the certified exchange rate of US$1.00 = RMB6.2301 on December 31, 2012 as set forth in the H.10 weekly statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted into US$ at that rate on December 31, 2012, or at any other date. The percentages stated are calculated based on RMB amounts.
ContactsZixin Shao, CFO
China Nepstar Chain Drugstore Ltd.
Chief Financial Officer
China Nepstar Chain Drugstore Ltd. Unaudited Condensed Consolidated Statements of Income and Comprehensive Income(amounts in thousands – except per-share data)Three-month period endedYear endedDecember 31,December 31,201120122012201120122012RMBRMBUSDRMBRMBUSDRevenue
409,280Cost of goods sold
189,490Sales, marketing and other operating
(162,388)General and administrative expenses
(18,577)Impairment losses of property and
238Income from operations
2,638Dividend income from cost method
727Equity in income of an equity method
215Income from disposal of an equity
10,985Income before income tax expense
22,100Income tax expense
14,461Basic earnings per ordinary share
0.07Basic earnings per ADS
0.14Diluted earnings per ordinary share
0.07Diluted earnings per ADS
0.14Other comprehensive income, net of tax:Foreign currency translation adjustments
(89)Comprehensive income attributable to
China Nepstar Chain Drugstore Ltd.
14,372 China Nepstar Chain Drugstore Ltd. Unaudited Condensed Consolidated Balance Sheets(amounts in thousands)As ofAs ofDecember 31,December 31,20112012RMBRMBUSDASSETSCurrent assetsCash and cash equivalents
59,591Short-term bank time deposits
5,778Accounts receivable, net of allowance for doubtful
18,395Amounts due from related parties
1,325Prepaid expenses, deposits and other current assets
76,802Deferred tax assets
274Total current assets
223,856Non-current assetsLong-term bank time deposits
3,210Property and equipment, net
6,137Cost method investments
2,029Equity method investment
-Intangible assets, net
8,318Deferred tax assets
491Deposits for acquisition
-Accrued interest income
81Total non-current assets
40,025Total Assets1,942,1971,644,011263,881LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilitiesAccounts payable
3,296Amounts due to related parties
2,950Accrued expenses and other payables
16,935Income tax payable
2,300Total current liabilities
89,213Non-current liabilitiesDeferred income
2,948Deferred tax liabilities
1,204Other non-current liabilities
5,816Total non-current liabilities
9,968Total liabilities587,943617,90899,181Shareholders' equityShare capital
-Additional paid-in capital
133,675Accumulated other comprehensive loss
37,691Total shareholders' equity
164,700Total liabilities and shareholders' equity1,942,1971,644,011263,881
|SOURCE China Nepstar Chain Drugstore Ltd.|
Copyright©2012 PR Newswire.
All rights reserved